Acrivon Net Income From Continuing Ops from 2010 to 2026
| ACRV Stock | 1.50 0.06 3.85% |
Net Loss | First Reported 2010-12-31 | Previous Quarter -72.5 M | Current Value -68.9 M | Quarterly Volatility 27.6 M |
Check Acrivon Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Acrivon Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 1.2 M, Selling General Administrative of 30.4 M or Total Revenue of 0.0, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 1.23. Acrivon financial statements analysis is a perfect complement when working with Acrivon Therapeutics Valuation or Volatility modules.
Acrivon | Net Income From Continuing Ops | Build AI portfolio with Acrivon Stock |
The evolution of Net Income From Continuing Ops for Acrivon Therapeutics Common provides essential context for understanding the company's financial health trajectory. By analyzing this metric's behavior over time, investors can assess whether recent trends align with long-term patterns, and how Acrivon Therapeutics compares to historical norms and industry peers.
Latest Acrivon Therapeutics' Net Income From Continuing Ops Growth Pattern
Below is the plot of the Net Income From Continuing Ops of Acrivon Therapeutics Common over the last few years. It is Acrivon Therapeutics' Net Loss historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Acrivon Therapeutics' overall financial position and show how it may be relating to other accounts over time.
| Net Income From Continuing Ops | 10 Years Trend |
|
Net Income From Continuing Ops |
| Timeline |
Acrivon Net Income From Continuing Ops Regression Statistics
| Arithmetic Mean | (22,221,928) | |
| Coefficient Of Variation | (123.99) | |
| Mean Deviation | 22,594,605 | |
| Median | (5,306,000) | |
| Standard Deviation | 27,552,185 | |
| Sample Variance | 759.1T | |
| Range | 75.2M | |
| R-Value | (0.80) | |
| Mean Square Error | 285.9T | |
| R-Squared | 0.65 | |
| Significance | 0.000099 | |
| Slope | (4,388,397) | |
| Total Sum of Squares | 12146T |
Acrivon Net Income From Continuing Ops History
About Acrivon Therapeutics Financial Statements
Acrivon Therapeutics investors use historical fundamental indicators, such as Acrivon Therapeutics' Net Income From Continuing Ops, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Acrivon Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Loss | -72.5 M | -68.9 M |
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Acrivon Stock Analysis
When running Acrivon Therapeutics' price analysis, check to measure Acrivon Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Acrivon Therapeutics is operating at the current time. Most of Acrivon Therapeutics' value examination focuses on studying past and present price action to predict the probability of Acrivon Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Acrivon Therapeutics' price. Additionally, you may evaluate how the addition of Acrivon Therapeutics to your portfolios can decrease your overall portfolio volatility.